Biomarker-Guided Adjuvant Therapy in Stage II/III Colon Cancer: A Systematic Review of Current Evidence and Clinical Implications
{{output}}
Background: The management of resectable stage II/III colon cancer (CC) has long relied on clinicopathological features and fluoropyrimidine-based adjuvant chemotherapy. However, this approach fails to capture the profound biolog... ...